1. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995; 86:3961–3969. PMID:
7579367.
Article
2. Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma. 2003; 44:815–820. PMID:
12802919.
Article
3. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009; 27:4767–4773. PMID:
19720922.
Article
4. Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of poor mobilizer in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano-Trapianto di Midollo Osseo. Bone Marrow Transplant. 2012; 47:342–351. PMID:
21625224.
Article
5. Basak GW, Jaksic O, Koristek Z, et al. Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol. 2011; 86:550–553. PMID:
21674573.
Article